Efficacy and safety of ipragliflozin as an add‐on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial

MLA

K.-H. Yoon, et al. “Efficacy and Safety of Ipragliflozin as an Add‐on Therapy to Sitagliptin and Metformin in Korean Patients with Inadequately Controlled Type 2 Diabetes Mellitus: A Randomized Controlled Trial.” Diabetes, Obesity & Metabolism, vol. 20, no. 10, July 2018, pp. 2408–15. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....a314097bda1b66b1fdb89ee4f32234c3&authtype=sso&custid=ns315887.

APA

K.-H. Yoon, Taishi Sakatani, Sumi Park, Chang Hee Jung, Soo Lim, Kyung Ah Han, Dong Sun Kim, Kwan Woo Lee, Suk Chon, Moon Kyu Lee, Inkyu Lee, Kyong Soo Park, Bong Soo Cha, Sei Hyun Baik, & Choon Hee Chung. (2018). Efficacy and safety of ipragliflozin as an add‐on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial. Diabetes, Obesity & Metabolism, 20(10), 2408–2415.

Chicago

K.-H. Yoon, Taishi Sakatani, Sumi Park, Chang Hee Jung, Soo Lim, Kyung Ah Han, Dong Sun Kim, et al. 2018. “Efficacy and Safety of Ipragliflozin as an Add‐on Therapy to Sitagliptin and Metformin in Korean Patients with Inadequately Controlled Type 2 Diabetes Mellitus: A Randomized Controlled Trial.” Diabetes, Obesity & Metabolism 20 (10): 2408–15. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....a314097bda1b66b1fdb89ee4f32234c3&authtype=sso&custid=ns315887.